BR112017022073A2 - método para purificação de proteína - Google Patents

método para purificação de proteína

Info

Publication number
BR112017022073A2
BR112017022073A2 BR112017022073A BR112017022073A BR112017022073A2 BR 112017022073 A2 BR112017022073 A2 BR 112017022073A2 BR 112017022073 A BR112017022073 A BR 112017022073A BR 112017022073 A BR112017022073 A BR 112017022073A BR 112017022073 A2 BR112017022073 A2 BR 112017022073A2
Authority
BR
Brazil
Prior art keywords
protein purification
provides
recovering
human
monomeric
Prior art date
Application number
BR112017022073A
Other languages
English (en)
Inventor
Barry Wild Gavin
Philip Heywood Sam
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of BR112017022073A2 publication Critical patent/BR112017022073A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a presente invenção proporciona um método para recuperar um anticorpo contendo domínio vh3 humano em forma monomérica. em particular, a presente invenção proporciona um novo método que permite a recuperação de anticorpos monoméricos contendo domínio vh3 humano de uma mistura contendo formas monoméricas e multiméricas do anticorpo.
BR112017022073A 2015-04-22 2016-04-20 método para purificação de proteína BR112017022073A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1506868.7A GB201506868D0 (en) 2015-04-22 2015-04-22 Method for protein purification
PCT/EP2016/058774 WO2016169992A1 (en) 2015-04-22 2016-04-20 Method for protein purification

Publications (1)

Publication Number Publication Date
BR112017022073A2 true BR112017022073A2 (pt) 2018-08-14

Family

ID=53299017

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017022073A BR112017022073A2 (pt) 2015-04-22 2016-04-20 método para purificação de proteína

Country Status (19)

Country Link
US (2) US10927164B2 (pt)
EP (1) EP3286205A1 (pt)
JP (2) JP6866300B2 (pt)
KR (1) KR20170139131A (pt)
CN (1) CN107636012B (pt)
AR (1) AR104358A1 (pt)
AU (1) AU2016251223B2 (pt)
BR (1) BR112017022073A2 (pt)
CA (1) CA2983057A1 (pt)
CL (1) CL2017002614A1 (pt)
CO (1) CO2017010631A2 (pt)
EA (1) EA201792328A1 (pt)
GB (1) GB201506868D0 (pt)
IL (1) IL254883B (pt)
MA (1) MA41941A (pt)
MX (1) MX2017013333A (pt)
MY (1) MY189854A (pt)
SG (1) SG11201708256YA (pt)
WO (1) WO2016169992A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9657055B2 (en) * 2011-11-30 2017-05-23 Ge Healthcare Bioprocess R&D Ab Affinity chromatography matrix
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
CN108085358A (zh) * 2018-02-08 2018-05-29 保定冀中药业有限公司 一种犬细小病毒单克隆抗体IgG2b-Fab片段的制备方法
CA3142610A1 (en) 2019-08-02 2021-02-11 UCB Biopharma SRL Methods for purifying antibodies
GB201919058D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
BR112022011993A2 (pt) * 2019-12-26 2022-09-20 Abl Bio Inc Método para purificar peptídeo biologicamente ativo usando cromatografia de afinidade de proteína a
GB202109246D0 (en) * 2021-06-28 2021-08-11 Cytiva Bioprocess R & D Ab A method of separating bispecific antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
EP1181052A4 (en) 1999-05-15 2004-08-11 Univ California San Diego AREAS WITH INTENDED ACTIVITIES BASED ON PROTEIN A
CN100374456C (zh) * 2000-12-29 2008-03-12 萨文特医药公司 用于选择性癌症治疗的特异性人抗体
EP1614693A4 (en) * 2003-03-31 2006-07-19 Kirin Brewery PURIFICATION OF A HUMAN MONOCLONAL ANTIBODY AND A HUMAN POLYCLONAL ANTIBODY
CA2733782A1 (en) * 2008-08-14 2010-02-18 Merck Sharp & Dohme Corp. Methods for purifying antibodies using protein a affinity chromatography
AU2010216152B2 (en) * 2009-02-17 2015-05-14 Ucb Biopharma Sprl Antibody molecules having specificity for human OX40
EA201300524A1 (ru) * 2010-11-01 2013-08-30 ДСМ АйПи АССЕТС Б.В. Очистка антител ионообменной хроматографией в едином блоке
WO2012074463A1 (en) 2010-11-29 2012-06-07 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
UA112203C2 (uk) * 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
CA2856216C (en) 2011-11-11 2021-01-12 Ucb Pharma S.A. Albumin binding antibodies and binding fragments thereof
WO2013119966A2 (en) * 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
SG10201909806SA (en) * 2013-11-04 2019-11-28 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method

Also Published As

Publication number Publication date
CL2017002614A1 (es) 2018-04-27
EP3286205A1 (en) 2018-02-28
KR20170139131A (ko) 2017-12-18
IL254883B (en) 2021-09-30
JP2018520089A (ja) 2018-07-26
JP2021066734A (ja) 2021-04-30
GB201506868D0 (en) 2015-06-03
US10927164B2 (en) 2021-02-23
US20180100007A1 (en) 2018-04-12
CN107636012B (zh) 2022-08-02
AR104358A1 (es) 2017-07-12
US20210171609A1 (en) 2021-06-10
MY189854A (en) 2022-03-14
AU2016251223A1 (en) 2017-10-26
CN107636012A (zh) 2018-01-26
WO2016169992A1 (en) 2016-10-27
AU2016251223B2 (en) 2021-12-09
IL254883A0 (en) 2017-12-31
EA201792328A1 (ru) 2018-05-31
SG11201708256YA (en) 2017-11-29
CO2017010631A2 (es) 2018-01-05
JP6866300B2 (ja) 2021-04-28
MA41941A (fr) 2018-02-28
MX2017013333A (es) 2018-02-19
CA2983057A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
BR112017022073A2 (pt) método para purificação de proteína
ZA202107931B (en) Anti-tau antibodies and methods of use
CL2020003409A1 (es) Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154)
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
ECSP18023386A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CR20190271A (es) Anticuerpos antitau y métodos de uso
EA202092435A2 (ru) Моноклональные антитела против bcma
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
MX2018008369A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
PH12016500940A1 (en) HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
MX2019006330A (es) Anticuerpos anti-tau y metodos de uso.
EA201691367A1 (ru) Кристаллические формы дималеата афатиниба
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
SG10201806454RA (en) Anti-tenascin c antibodies and uses thereof
GB201811403D0 (en) Antibody molecules
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]